UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 252

Sortiert nach

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Clinical cancer research, 2020-08, Vol.26 (16), p.4280-4288

2020

Volltextzugriff (PDF)

FDA Approval: Blinatumomab

Clinical cancer research, 2015-09, Vol.21 (18), p.4035-4039

2015

Volltextzugriff (PDF)

FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease

The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.e328-e334

2020

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Clinical cancer research, 2013-09, Vol.19 (17), p.4559-4563

2013

Volltextzugriff (PDF)

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Journal of clinical oncology, 2022-03, Vol.40 (8), p.847-854

2022

Volltextzugriff (PDF)

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

Clinical cancer research, 2020-01, Vol.26 (2), p.328-331

2020

Volltextzugriff (PDF)

Considerations in the development of circulating tumor cell technology for clinical use

Journal of translational medicine, 2012-07, Vol.10 (1), p.138-138, Article 138

2012

Volltextzugriff (PDF)

Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

Leukemia, 2020-11, Vol.34 (11), p.3082-3084

2020

Volltextzugriff (PDF)

EBNA1 Regulates Cellular Gene Expression by Binding Cellular Promoters

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (52), p.22421-22426

2009

Volltextzugriff (PDF)

Damage associated molecular pattern molecules

Clinical immunology (Orlando, Fla.), 2007-07, Vol.124 (1), p.1-4

2007

Volltextzugriff (PDF)

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2078-2085

2007

Volltextzugriff (PDF)

An Adenoviral Vector Cancer Vaccine That Delivers a Tumor-Associated Antigen/CD40-Ligand Fusion Protein to Dendritic Cells

Proceedings of the National Academy of Sciences - PNAS, 2003-12, Vol.100 (25), p.15101-15106

2003

Volltextzugriff (PDF)

Normal and Pathological Functions of Mammalian Retroelements

Proceedings of the National Academy of Sciences - PNAS, 2005-08, Vol.102 (35), p.12292-12293

Deisseroth, Albert

2005

Volltextzugriff (PDF)

Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy

Molecular therapy, 2007-06, Vol.15 (6), p.1065-1071

2007

Volltextzugriff (PDF)

Vaccination of Rabbits with an Adenovirus Vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and Infection

Journal of Virology, 2004-01, Vol.78 (1), p.116-123

2004

Volltextzugriff (PDF)

p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation

Cancer research (Chicago, Ill.), 1995-02, Vol.55 (3), p.668-674

1995

Volltextzugriff (PDF)

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

Clinical cancer research, 2019-01, Vol.25 (2), p.473-477

2019

Volltextzugriff (PDF)

STAT3-Mediated Signaling in the Determination of Rod Photoreceptor Cell Fate in Mouse Retina

Investigative ophthalmology & visual science, 2004-07, Vol.45 (7), p.2407-2412

2004

Volltextzugriff (PDF)

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression

Molecular and Cellular Biology, 1995-06, Vol.15 (6), p.3032-3040

1995

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Clinical cancer research, 2019-06, Vol.25 (11), p.3205-3209

2019

Volltextzugriff (PDF)

Vector Targeting Makes 5-Fluorouracil Chemotherapy Less Toxic and More Effective in Animal Models of Epithelial Neoplasms

Clinical cancer research, 2004-11, Vol.10 (22), p.7738-7746

2004

Volltextzugriff (PDF)

Methods for delivery of adenoviral vectors to tumor vasculature

Human gene therapy, 2007-02, Vol.18 (2), p.151

2007

Volltextzugriff (PDF)

Genetic Systems for the Diagnosis and Treatment of Human Disease

Cancer biology & therapy, 2004-01, Vol.3 (1), p.126-131

Deisseroth, Albert

2004

Volltextzugriff (PDF)

Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon

Cancer gene therapy, 2003-05, Vol.10 (5), p.388-395

2003

Volltextzugriff (PDF)

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Clinical cancer research, 2015-03, Vol.21 (5), p.950-954

2015

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(240)
Mit Volltextzugriff
(224)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(189)
Life Sciences & Biomedicine
(180)
Humans
(179)
Biological And Medical Sciences
(88)
Oncology
(71)
Medical Sciences
(70)
Female
(69)
Hematology
(59)
Animals
(57)
Adult
(50)
Male
(49)
Middle Aged
(47)
Base Sequence
(33)
Mice
(31)
Hematologic And Hematopoietic Diseases
(29)
Molecular Sequence Data
(29)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(27)
Aged
(26)
Pharmacology. Drug Treatments
(24)
Tumor Cells, Cultured
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

FDA Approval: Blinatumomab

FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

Considerations in the development of circulating tumor cell technology for clinical use

Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

EBNA1 Regulates Cellular Gene Expression by Binding Cellular Promoters

Damage associated molecular pattern molecules

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

An Adenoviral Vector Cancer Vaccine That Delivers a Tumor-Associated Antigen/CD40-Ligand Fusion Protein to Dendritic Cells

Normal and Pathological Functions of Mammalian Retroelements

Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy

Vaccination of Rabbits with an Adenovirus Vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and Infection

p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

STAT3-Mediated Signaling in the Determination of Rod Photoreceptor Cell Fate in Mouse Retina

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Vector Targeting Makes 5-Fluorouracil Chemotherapy Less Toxic and More Effective in Animal Models of Epithelial Neoplasms

Methods for delivery of adenoviral vectors to tumor vasculature

Genetic Systems for the Diagnosis and Treatment of Human Disease

Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Aktive Filter

Suchergebnisse filtern